Inovira

Inosine Pranobex, the active ingredient in Inovira, is an immunostimulant presented as an oral tablet for oral administration. It is employed to enhance immune function in viral infections such as herpes simplex, influenza, and in patients with immunodeficiency‑related viral diseases.

GNH USA supplies Inovira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards and ensures product quality through rigorous quality‑control processes.

Inosine Pranobex is used to modulate immune responses in viral infections and related conditions.

- Herpes simplex virus infections: reduces lesion frequency and accelerates healing. - Influenza and other acute viral respiratory infections: shortens disease duration and alleviates symptoms. - Subacute sclerosing panencephalitis (SSPE): supports antiviral activity in progressive measles complications. - Human papillomavirus (HPV) warts: promotes regression of cutaneous lesions. - Immunodeficiency‑related viral infections: enhances host defense against opportunistic viruses.

Inosine Pranobex may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Fatigue: feeling of reduced energy. - Gastrointestinal discomfort: abdominal pain or cramping. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling of face or throat. - Hepatotoxicity: abnormal liver enzyme elevations. - Hematologic abnormalities: leukopenia or thrombocytopenia. - Cardiac arrhythmias: irregular heart rhythm in susceptible individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy with Inosine Pranobex, consider the following precautions.

- Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; weigh benefits against potential infant exposure. - Liver disease: monitor hepatic function regularly. - Renal impairment: dose adjustment may be required based on renal function. - Immunocompromised patients: close clinical monitoring is advised. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Inosine Pranobex can interact with other medicines; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may counteract immunostimulatory effect. - Live vaccines: increased risk of adverse vaccine reactions.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): possible alteration of coagulation parameters. - Antiretroviral agents: potential for reduced antiviral efficacy. - CNS depressants: may enhance sedation or dizziness. - Herbal immunomodulators (e.g., echinacea): additive immune stimulation. - Diuretics: monitor electrolyte balance.